Literature DB >> 9694351

Response to hepatitis B vaccine: multiple HLA genes are involved.

I Desombere1, A Willems, G Leroux-Roels.   

Abstract

The mechanism underlying the impaired immune response to hepatitis B vaccines in up to 10% of healthy subjects is not known. An increased incidence of poor responsiveness in subjects with HLA-DR3+ or -DR7+ haplotypes has been documented, suggesting that HLA-DR-linked genes may regulate the human response to hepatitis B surface antigen. However, not all HLA-DR3+ and/or -DR7+ individuals are poor responders, and subjects with identical HLA-DR haplotypes sometimes display totally divergent antibody responses to vaccination. HLA class II DNA typing was performed in well and poorly responding hepatitis B vaccine recipients and we analyzed the role of the single HLA-DR, -DP, and -DQ molecules and of their associated (interaction) haplotypes in the response to hepatitis B vaccination. Statistical analysis revealed that HLA-DRB1*010*, -DR5, -DPB1*040*, -DQB1*0301, and -DQB1*0501 were more abundant in good responders, whereas HLA-DRB1*07, -DPB1*1101, and -DQB1*020* were associated with poor response, with DQB1*020* showing the strongest association with poor responsiveness. We further investigated whether there were interactions between the HLA factors contributing to poor responsiveness. We show here that HLA-DPB1*02 was negatively associated with responsiveness when it occurred in association with haplotype DRB1*0701/DRB4*0101-DQB1*020*, and DRB4*0101 was negatively associated with responsiveness when it occurred in association with haplotype DRB1*0301/DRB3*0101-DQB1*020*. Our results indicate that the immune response to hepatitis B vaccine is largely determined by HLA-DR, -DP, and -DQ genes and that interaction between HLA molecules that are not in linkage disequilibrium contributes to poor responsiveness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694351     DOI: 10.1111/j.1399-0039.1998.tb03001.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  40 in total

1.  Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines.

Authors:  I Desombere; Y Gijbels; A Verwulgen; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation.

Authors:  I Desombere; T Cao; Y Gijbels; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

3.  Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines.

Authors:  Vijayakumar Velu; Shanmugam Saravanan; Subhadra Nandakumar; Esaki-Muthu Shankar; Appasamy Vengatesan; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

4.  T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals.

Authors:  Martin R Weihrauch; Michael von Bergwelt-Baildon; Milos Kandic; Martin Weskott; Winfried Klamp; Joachim Rosler; Joachim L Schultze
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 5.  Searching for the human genetic factors standing in the way of universally effective vaccines.

Authors:  Alexander J Mentzer; Daniel O'Connor; Andrew J Pollard; Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

6.  Humoral responses to independent vaccinations are correlated in healthy boosted adults.

Authors:  Lori Garman; Amanda J Vineyard; Sherry R Crowe; John B Harley; Christina E Spooner; Limone C Collins; Michael R Nelson; Renata J M Engler; Judith A James
Journal:  Vaccine       Date:  2014-08-17       Impact factor: 3.641

7.  In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model.

Authors:  T Cao; P Meuleman; I Desombere; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

9.  Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.

Authors:  Isabelle Desombere; Annick Willems; Yvonne Gijbels; Geert Leroux-Roels
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 10.  Application of pharmacogenomics to vaccines.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Pharmacogenomics       Date:  2009-05       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.